Keyphrases
A1 Receptor
33%
Capital Region
33%
Changes in Body Weight
33%
Declaration of Helsinki
33%
Denmark
33%
Dietary Weight Loss
33%
End of Treatment
33%
Ethical Committee
33%
Ethics
33%
GLP-1 Receptor Agonist
100%
Glucagon-like
33%
Good Clinical Practice
33%
Health Outcomes
33%
Investigator-initiated
33%
Liraglutide
100%
Liraglutide 3.0 Mg
66%
Low-calorie Diet
100%
Obesity
33%
Obesity Body Mass Index
33%
Parallel Trials
33%
Physical Exercise
33%
Placebo
100%
Randomized Controlled Trial
100%
Randomized Placebo-controlled Trial
33%
Receptor Agonist
33%
Scientific Journals
33%
Success Rate
33%
Weight Loss
100%
Weight Maintenance
33%
Medicine and Dentistry
Body Mass Index
25%
Body Weight
50%
Glucagon-Like Peptide-1 Agonist
100%
Group Trial
25%
Health Outcomes
25%
Liraglutide
100%
Medicine
25%
Placebo
100%
Randomized Controlled Trial
100%
Very Low Calorie Diet
100%
